Omni Bio Pharmaceutical — Investor Presentation (July 2013)
27 slides from Omni Bio Pharmaceutical's investor presentation, Jul 2, 2013

Slide 1: An Overview of Omni Bio Pharmaceutical, Inc.
An Overview of Omni Bio Pharmaceutical, Inc. A Company Focused on Monetizing Assets and Creating Breakthrough Therapies Bruce Schneider, Ph.D. July, 2013

Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

Slide 3: Topics to be Addressed
Topics to be Addressed e Overview e Our Team e Plasma Product Profile/Licensing e Recombinant Fc-AAT e Fe-AAT Science Highlights e Fc-AAT Development Plan e Financing Needs/Plans e Summary 3 OP niBio

Slide 4: Quick Overview of Omni
~ Quick Overview of Omni e Public company since 2009 (symbol OMBP.OB) e Initially focused on promoting & licensing new uses of plasma-derived alpha-1 antitrypsin (p-AAT) © Now developing “Enbrel-like” recombinant Fc fusion proteins (Fc-AATs) e Unusually broad potential e Highly competitive profiles

Slide 5: Our Team
Our Team e CEO- Bruce Schneider, PhD e Over 35 years experience in drug development « Mostrecently EVP & Chief of Research Operations at Wyeth/Pfizer e CSO- Charles Dinarello, MD ¢ World recognized “father” of cytokine biology ¢ Current affiliations with Univ of Colorado and Radboud Univ (Netherland

Slide 6: What's Plasma-derived AAT (p-AAT)?
$$ What’s Plasma-derived AAT (p-AAT)? e Naturally occurring protease inhibitor with anti- inflammatory and tissue protective effects e Extracted and purified from whole human blood e Currently approved to treat AAT-deficient patients e Emphysema, COPD e Product characteristics 25 year safety record

Slide 7: Data Highlights - Type 1 Diabetes
Data Highlights - Type 1 Diabetes AAT treatment preserves islet cell function (essential for insulin production) Insulin Glucagon ge A Bee é —LinsulintAAT Control 2 +4 Insulin Control 5 1 c é G1 10 a0 20 00 p-AAT Treated Days attor intial therapy 3 : 2 (Sis oe Glucose normalized with AAT for tet his

Slide 8: Data Highlights - Type 1 Diabetes
Data Highlights - Type 1 Diabetes AAT treatment preserves islet cell function (essential for insulin production) Insulin Glucagon ge A Bee é —LinsulintAAT Control 2 +4 Insulin Control 5 1 c é G1 10 a0 20 00 p-AAT Treated Days attor intial therapy 3 : 2 (Sis oe Glucose normalized with AAT for tet his

Slide 9: Data Highlights — Graft vs Host Disease
Data Highlights — Graft vs Host Disease AAT reduces mortality from GvHD in mouse transplant model 100 ad _ 80 = 60 -® Matched Transplant (n=8) s 3 -f& Mis-matched Transplant (n=9) a 40 —¥% Mis-matched Transplant 20 + p-AAT (n=9) 0 SEER 0 10 20 30 40 50 60 70 Days after BMT Tawara| et al. PNAS 2012;1

Slide 10: Data Highlights — Cardiac Re-Modeling
Data Highlights — Cardiac Re-Modeling AAT reduces acute myocardial infarct size in mouse model Infarct Infarct N=6 pergroup * P<O.05vssham ** P<0.05 vs Albumin Toldo et al. (2011) J Mol Cell Cardiol 61(2): 244-51 5 OF hiBio

Slide 11: Licenses in Multiple Areas
Licenses in Multiple Areas e Diabetes mellitus e GvHD and non-organ transplantation rejection e Radioprotection e Certain bacterial infections © Certain viral infections e Postinfarction myocardial remodeling Inflammatory bowel disease (GI wasting) “Licensed method-of-use patents issued or pending i

Slide 12: Omni's IP Monetization Strategy
Omni’s IP Monetization Strategy e Sub-license patents to one or more of the four p-AAT manufacturers e Exclusive or non-exclusive e Seeking up-front, milestone and royalty payments © Clinical data-dependent e Explore Omni-owned supply strategy e Omni buys “excess” capacity ¢ Markets/sells into indic

Slide 13: Licensing: New Clinical Trials
; ‘Licensing New Clinical Trials e Type 1 Diabetes ° Three pilot studies completed (Omni Bio, Immune Tolerance Network, Kamada) e Loss of pancreatic beta cell function (essential for insulin production) slowed/halted in certain patients e Graft vs Host Disease (GvHD) e Affects ~50% of all bone marro

Slide 14: Omni Bio's Type 1 Diabetes Trial
Omni Bio’s Type 1 Diabetes Trial Results suggest stabilization of C-peptide levels (a measure of insulin- producing beta cell function) Blue = adult = 600 AAT Rx Red = pediatric ° 3 6 Months Gottlieb Data: Initial 6 month results from second new onset cohort, June 2012 4 OP niBio

Slide 15: ITN's Type 1 Diabetes Pilot Study
ITN’s Type 1 Diabetes Pilot Study ‘C-peptide Mean 2-hour AUC (pmolimL) Results also demonstrate stabilization of C-peptidelevels 2.0 1.5 1.0 0.5 0.0 = = Pediatric => Adult Mean change from baseline + Adult| +0.013 (p=0.852) + Pediatric: -0.191 (p=0.148) 0 100 200 300 400 Study Day NIH's Immune Toler

Slide 16: Fc-AAT
: ew Opp Fo-AAT e Key attributes of Omni’s lead molecule: e 40-50x more potent than p-AAT in various animal models e Overcomes problems seen with stand-alone recombinants e Longer duration of effect seen in some models e Able to be self-administered via subcutaneous injection e Can be made in large

Slide 17: Fc-AAT is a Protein Fusion Molecule
Fc-AAT is a Protein Fusion Molecule Recombinant AAT uN Human IgG1-Fe —> Q Configuration similar to Enbrel Q Fc fusion molecules designed to extend duration of action Q Fc fusion molecules well- known to regulatory authorities OF hiBio

Slide 18: Data Highlights — Inflammation (1)
Data Highlights — Inflammation (1) Fc-AAT produces dose-dependent reductions in joint inflammation in gout arthritis model 2 p<0.001 12 p<0.001 Joint swelling (0-3) il I IL-1p (pg/mL) ee|eg tH Fs SS Kg tener eae ef © sg ef Fs 4 hours after chemical-induced inflammation Zi OF hiBio

Slide 19: Data Highlights — Inflammation (2)
Data Highlights — Inflammation (2) Fe-AAT highly effective in clearing granular infiltrates that cause inflammation in gout model Ivig 50ug AAT-Fc 50ug 4 hours after chemical-induced inflammation 5 OF hiBio

Slide 20: Data Highlights — Inflammation (3)
Data Highlights — Inflammation (3) Fc-AAT 50 meg at least as effective as p-AAT 2 mg and competitive with high-dose IL-Ra (anakinra) in gout model Joint swelling (0-3) 1 =o —— p<0001 | P<0.001, = 2. =o z —— 1 Pane i 3 10 = 5 00 2 2 2 s a ~ & af x e 4 hours after chemical-induced inflammation OF hiBi

Slide 21: Fc-AAT Value Creation Strategies
Se Fc-AAT Value Creation Strategies e Fast-to-Market Option ¢ Position as a “bio-better” product to replace p-AAT for existing emphysema indication e May only require early phase 1 work followed by a single phase 2/3 study demonstrating equivalence to existing product and lack of immunogenicity e De

Slide 22: Attractive Market Opportunities
Attractive Fast-to-Market Option Disease Market Size (US/EU) AAT Replacement Therapy ~$500M Potential First New Indications Disease Market Size (US/EU) Type 1 Diabetes (Early Onset) >$1B Graft vs Host Disease ~$500M Gout (Treatment Refractory) >$1B Options For Life Cycle Management Disease Market Si

Slide 23: Detailed Development Plan Created
Detailed Development Plan Created* 2011 2012 2013 2014 2015 2016 @lala ale lala ale (alalale lala alalalealaleale Fe-AAT Early Development Plan (Overview) Selection of Candidate Molecule Pre-Clinical Animal Model POC (SD Pilot Toxicology (I Coll Line Selection & Establish MCB. GS Process Dev. Early

Slide 24: Financing Needs and Decision Points
tment to Reac Decision Points © $1.5M per year needed for ongoing operating expenses e $5-6M needed to complete preclinical development (now) + Process/formulation/analytical development + Ancillary pharmacology & pilot toxicology studies + GMP clinical trial material (drug product) + IND enabling a

Slide 25: Potential Fc-AAT “Exit” Strategies
SS Potential Fc-AAT “Exit” Strategies e Proceed with self-funded development through first patient studies then license to established pharma e 3-4 year outlook e Potential 5-10x value play but also greatest funding requirement e Partner with established pharma player to fund or co- fund next develo

Slide 26: Corporate Information
Corporate Information e Stock symbol OMBP.OB ¢ Closing stock price (7/1/13) $0.30 ° 52-week range $0.17-0.60 e Shares outstanding 38.2 million e Fully diluted shares 66.4 million e Market capitalization (7/1/13) $11.5 million e Fiscal year-end March 31 e Cash on hand (7/1/13) $1.3 million 26 OF niBi

Slide 27: Omni Summary
~ Omni Summary e Licensing efforts to monetize p-AAT method-of-use patents underway e Our centerpiece recombinant Fc-AAT program has very broad, high value potential e The Fc-AAT development plan e Includes a valuable fast-to-market option e Is well-defined and predictably executed e Is supported by
Source: SEC EDGAR · 8-K filed Jul 2, 2013
More decks from Omni Bio Pharmaceutical Inc
Investor Presentation (September 2014)27 slides · Sep 11, 2014
Investor Presentation (June 2014)26 slides · Jun 3, 2014
Investor Presentation (September 2013)24 slides · Sep 9, 2013
Investor Presentation (February 2013)20 slides · Feb 12, 2013
Investor Presentation (March 2012)25 slides · Mar 20, 2012
Noble Financial Capital Markets' Eighth Annual Equity Conference 201240 slides · Jan 17, 2012